Similar articles for PMID: 28729431

Year	Number of Results
1990	1
1992	1
1993	1
2002	1
2005	1
2006	1
2008	1
2009	3
2010	5
2011	6
2012	5
2013	11
2014	18
2015	14
2016	31
2017	29
2018	28
2019	61
2020	56
2021	60
2022	38
2023	26
2024	1

1

Long-Acting Somatostatin Analog Therapy Differentially Alters ⁶⁸Ga-DOTATATE Uptake in Normal Tissues Compared with Primary Tumors and Metastatic Lesions.

Ayati N, Lee ST, Zakavi R, Pathmaraj K, Al-Qatawna L, Poon A, Scott AM. Ayati N, et al. J Nucl Med. 2018 Feb;59(2):223-227. doi: 10.2967/jnumed.117.192203. Epub 2017 Jul 20. J Nucl Med. 2018. PMID: 28729431 Free article.

2

A Prospective Observational Study to Evaluate the Effects of Long-Acting Somatostatin Analogs on ⁶⁸Ga-DOTATATE Uptake in Patients with Neuroendocrine Tumors.

Gålne A, Almquist H, Almquist M, Hindorf C, Ohlsson T, Nordenström E, Sundlöv A, Trägårdh E. Gålne A, et al. J Nucl Med. 2019 Dec;60(12):1717-1723. doi: 10.2967/jnumed.119.226332. Epub 2019 Apr 18. J Nucl Med. 2019. PMID: 31000584 Free PMC article.

3

Influence of lanreotide on uptake of ⁶⁸Ga-DOTATATE in patients with neuroendocrine tumours: a prospective intra-patient evaluation.

Aalbersberg EA, de Wit-van der Veen BJ, Versleijen MWJ, Saveur LJ, Valk GD, Tesselaar MET, Stokkel MPM. Aalbersberg EA, et al. Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):696-703. doi: 10.1007/s00259-018-4117-x. Epub 2018 Aug 10. Eur J Nucl Med Mol Imaging. 2019. PMID: 30097670 Clinical Trial.

4

Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.

Jois B, Asopa R, Basu S. Jois B, et al. Clin Nucl Med. 2014 Jun;39(6):505-10. doi: 10.1097/RLU.0000000000000429. Clin Nucl Med. 2014. PMID: 24662668

5

68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.

Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, Brandau W, Bockisch A, Boy C. Poeppel TD, et al. J Nucl Med. 2011 Dec;52(12):1864-70. doi: 10.2967/jnumed.111.091165. Epub 2011 Nov 9. J Nucl Med. 2011. PMID: 22072704 Free article. Clinical Trial.

6

MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with ⁶⁸Ga-DOTATATE and ¹⁸F-FDG and Multimodality Anatomic Imaging in Metastatic Neuroendocrine Tumors of Unknown Primary in a PRRT Workup Setting.

Sampathirao N, Basu S. Sampathirao N, et al. J Nucl Med Technol. 2017 Mar;45(1):34-41. doi: 10.2967/jnmt.116.185777. Epub 2017 Feb 2. J Nucl Med Technol. 2017. PMID: 28154019 Free article.

7

Treatment with octreotide does not reduce tumor uptake of (68)Ga-DOTATATE as measured by PET/CT in patients with neuroendocrine tumors.

Haug AR, Rominger A, Mustafa M, Auernhammer C, Göke B, Schmidt GP, Wängler B, Cumming P, Bartenstein P, Hacker M. Haug AR, et al. J Nucl Med. 2011 Nov;52(11):1679-83. doi: 10.2967/jnumed.111.089276. Epub 2011 Oct 5. J Nucl Med. 2011. PMID: 21976529 Free article. Clinical Trial.

8

¹⁸F-AlF-NOTA-Octreotide Outperforms ⁶⁸Ga-DOTATATE/NOC PET in Neuroendocrine Tumor Patients: Results from a Prospective, Multicenter Study.

Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Boeckxstaens L, Dekervel J, Vandamme T, Lybaert W, den Broeck BV, Laenen A, Clement PM, Geboes K, Cutsem EV, Stroobants S, Verslype C, Bormans G, Deroose CM. Pauwels E, et al. J Nucl Med. 2023 Apr;64(4):632-638. doi: 10.2967/jnumed.122.264563. Epub 2022 Oct 20. J Nucl Med. 2023. PMID: 36265911 Free article.

9

Standardized uptake values and ratios on 68Ga-DOTATATE PET-computed tomography for normal organs and malignant lesions and their correlation with Krenning score in patients with metastatic neuroendocrine tumors.

Menon BK, Kalshetty A, Bhattacharjee A, Basu S. Menon BK, et al. Nucl Med Commun. 2020 Oct;41(10):1095-1099. doi: 10.1097/MNM.0000000000001253. Nucl Med Commun. 2020. PMID: 32732598

10

Changes in biodistribution on ⁶⁸Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression.

Cherk MH, Kong G, Hicks RJ, Hofman MS. Cherk MH, et al. Cancer Imaging. 2018 Jan 24;18(1):3. doi: 10.1186/s40644-018-0136-x. Cancer Imaging. 2018. PMID: 29361984 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

345 results

Results by year